HEPHAISTOS-Pharma

HEPHAISTOS-Pharma is a preclinical biotech company developing the next generation of immunostimulants against cancer, revolutionizing immune stimulation with a unique technology for intravenous administration, opening the way to metastatic and hard-to-treat indications. HEPHAISTOS-Pharma is the laureate of prestigious grants such as Bpifrance i-Nov and EIC accelerator in Europe and is also part of the SyStInn consortium laureate from the French National Research Agency for its clinical research program. HEPHAISTOS-Pharma is funded by the government program France 2030, the European Union - Next Generation EU through the France Relance Program and the European Innovation Council as part of the EIC accelerator program.